RE: Telegraph article25 Nov 2020 06:47
Yes it is a tip for SNG. Here is the article:
‘The advent of three viable coronavirus vaccines is great news – unless, like London-quoted Synairgen, you make treatments for the disease.
On Nov 9, when the success of the Pfizer/ BioNTech vaccine was announced, shares in the firm fell by 39pc. They had jumped more than fivefold on July 20, when the success of its own treatment for Covid-19 in hospital trials was reported.
It is easy to see investors’ logic: if we are all going to be vaccinated against the virus over the next few months, there will be far fewer people admitted to hospital with the disease and much less need for treatments.
That may be true. But the success against coronavirus of Synairgen’s treatment, a drug called interferon beta in a form delivered directly to the lungs, suggests that it could be effective against other respiratory diseases that we cannot expect to disappear in the next year or so.
This at least is the view of one fund manager Questor spoke to and also of analysts at Numis, the broker.
Now stockbrokers’ analysts can get carried away so perhaps we should take Numis’s share price target of 990p – more than 11 times the current price – with a pinch of salt. But the stock, which is quoted on Aim, may be worth a flutter with a small slice of your Isa or pension.’